Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Fiche publication
Date publication
août 2022
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Pr MALOUF Gabriel
Tous les auteurs :
Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG
Lien Pubmed
Résumé
MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive subgroup of renal cell carcinoma harboring high expression of c-MET. While TRCC response rates to VEGF receptor tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors are limited, efficacy of cabozantinib (a VEGFR, MET, and AXL inhibitor) in this subgroup is unclear.
Mots clés
MiT family translocation renal cell carcinoma, cabozantinib, non-clear cell renal cell carcinoma
Référence
Oncologist. 2022 08 18;: